Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3243 | Placebo control (non-behavioral infographic) Wiki | 0.50 |
| drug4162 | Stools Wiki | 0.50 |
| drug4866 | blood tests Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug5136 | placebo rinse Wiki | 0.50 |
| drug708 | Brief informational infographic Wiki | 0.50 |
| drug2190 | Intra-articular corticosteroid injection Wiki | 0.50 |
| drug765 | CLBS119 Wiki | 0.50 |
| drug760 | CHX0.12+CPC0.05 oral rinse (PerioAidActive Control) Wiki | 0.50 |
| drug2763 | Nasopharyngeal swabs Wiki | 0.35 |
| drug697 | Brequinar Wiki | 0.35 |
| drug3195 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013166 | Spondylitis NIH | 0.50 |
| D013167 | Spondylitis, Ankylosing NIH | 0.50 |
| D015535 | Arthritis, Psoriatic NIH | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001168 | Arthritis NIH | 0.45 |
| D001172 | Arthritis, Rheumatoid NIH | 0.39 |
| D001167 | Arteritis NIH | 0.35 |
| D011111 | Polymyalgia Rheumatica NIH | 0.29 |
| D013700 | Giant Cell Arteritis NIH | 0.29 |
| D012859 | Sjogren's Syndrome NIH | 0.25 |
| D020370 | Osteoarthritis, Knee NIH | 0.22 |
| D001327 | Autoimmune Diseases NIH | 0.22 |
| D008180 | Lupus Erythematosus, Systemic NIH | 0.20 |
| D003095 | Collagen Diseases NIH | 0.17 |
| D012216 | Rheumatic Diseases NIH | 0.15 |
| D003141 | Communicable Diseases NIH | 0.03 |
| D007239 | Infection NIH | 0.02 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001369 | Arthritis HPO | 0.45 |
| HP:0001370 | Rheumatoid arthritis HPO | 0.39 |
| HP:0012089 | Arteritis HPO | 0.35 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0005086 | Knee osteoarthritis HPO | 0.22 |
| HP:0002960 | Autoimmunity HPO | 0.22 |
| HP:0002725 | Systemic lupus erythematosus HPO | 0.20 |
Navigate: Correlations HPO
There are 4 clinical trials
Osteoarthritis (OA) is a condition affecting the whole joint and is a major cause of pain and disability worldwide. Although OA is very common, the initial steps which lead to the development of pain and tissue damage are not fully understood. In this study participants will be investigated for markers in the blood, joint and urine in people who have a diagnosis of osteoarthritis or inflammatory arthritis and are receiving a steroid injection for their condition. Markers will be evaluated in participants with osteoarthritis compared with other types of arthritis, including rheumatoid arthritis and spondyloarthritis.
Description: Pain outcome measure. The Numerical Rating Scale for pain has a range of 0 - 10, with the lowest score being 0 and the highest rating at 10.The pain rating will be reported by the participants for their symptomatic knee
Measure: Change from Baseline Numerical Rating Scale (NRS) for pain in target knee after 3 months Time: Baseline (Visit 1) and 3 months after treatment (Visit 2)Description: Protein measurements in serum, urine and synovial fluid for type II collagen degradation products in the samples. The levels of type II collagen degradation products may range from 0 to greater than 500 ng/mmol, depending on the stage and severity of the condition
Measure: Change in Biomarkers 3 months following treatment Time: Baseline (Visit 1) and 3 months after treatment (Visit 2)The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern. In European countries such as Spain, Italy, Germany, Portugal, England and France, the pandemic has been of utmost importance. To date, no treatment has been robustly validated, and two theoretically opposite therapeutic strategies are proposed, based either on antiretroviral therapy or on immunomodulating agents. In this complex context, people living with immune-mediated inflammatory diseases (IMID) raise specific concerns due to their potentially increased risk of infections or of severe infections. Among IMID, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis and giant cell arteritis are some key diseases. In this cross-sectional, observational, multi-centric study, the investigators aim to assess both clinical and serological prevalence of COVID-19 among samples of IMID patients in Europe. In parallel, the investigators aim to compare the prevalence of COVID-19 seroconversion across these five IMIDs, their penetration across different 6 European countries (France, Italy, Spain, Germany, United Kingdom and Portugal), and to assess the severity of COVID-19 in these patients. Moreover, changes in treatment will be assessed, including immunomodulatory tapering or discontinuation, its causes over the outbreak period, as well as the incidence of IMID flares and their severity over this same period. Finally, patient's perceptions towards the pandemic will be evaluated and compared to medication beliefs. Data will be collected through questionnaires during medical visit or phone consultation and serological tests will be performed within routine blood collection. As so, all study procedures are comprised within usual care. Through this study the investigators expect to have a better knowledge of the clinical and serological prevalence of COVID-19 in IMID across Europe, along with the psychological, clinical, and therapeutic impact of COVID-19 in this particular patient population.
Description: ELISA tests for COVID-19 antibodies
Measure: COVID-19 seroconversion Time: 1 day, during routine blood collectionDescription: Case report form filled by the health professional
Measure: COVID-19 infection Time: During medical visit or phone consultation, up to 2 hoursDescription: Descriptive analysis for each disease's rate
Measure: Seroconversion rate by disease Time: 1 day, during routine blood collectionDescription: Descriptive analysis for each country's rate
Measure: Penetration across Europe Time: 1 day, during routine blood collectionDescription: World Health Organization ordinal scale for clinical improvement at any given point of the infection, going from 0 to 8, where higher scores means worse outcome.
Measure: COVID-19 severity Time: During medical visit, up to 1 hourDescription: Descriptive analysis for overall and COVID-19-linked mortality rates
Measure: COVID-19 mortality rate Time: During contact with family members, up to 1 hourDescription: Case report form filled by the health professional
Measure: COVID-19 impact on immunomodulatory treatment Time: During medical visit, up to 1 hourDescription: Case report form filled by the patient
Measure: Patient-reported flares Time: During medical visit, up to 1 hourDescription: Fear of COVID-19 scale, going from 7 to 35, where higher scores means worse outcome.
Measure: Patient's fears towards COVID-19 Time: During medical visit, up to 1 hourDescription: Beliefs about Medicines Questionnaire, going from 11 to 55, with higher scores indicating stronger beliefs regarding medicine.
Measure: Patient's beliefs in their medicines towards COVID-19 Time: During medical visit, up to 1 hourThe purpose of this study is to assess whether immunosuppressive therapies used by patients with chronic inflammatory rheumatic diseases have an impact on the viral load and the humoral and cellular responses during viral infection with SarSCoV2, compared to members of their family cluster infected with the same viral strain.
Description: Nasopharyngeal swabs : Detection of SarS-Cov-2 RNA
Measure: Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs Time: up to Day 30Description: Nasopharyngeal swabs : Detection of SarS-Cov-2 RNA
Measure: Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs Time: between Day 30 and Day 90The prevalence of SARS-CoV-2 infection in chronic inflammatory rheumatic diseases has not yet been widely reported, and has been evaluated only in symptomatic patient samples. The proportion of asymptomatic or mildly symptomatic patients is unknown, in patients who share common symptoms with CoV-2-SARS infection. Our objective is to describe the prevalence of seroconversion to CoV-2-SARS by consecutive screening in routine care of patients with chronic inflammatory rheumatism with serological testing
Description: Proportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis
Measure: Proportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis Time: 1 dayDescription: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments.
Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments. Time: 1 dayDescription: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease
Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease Time: 1 dayDescription: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristics
Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristics Time: 1 dayAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports